PMID- 25468310
OWN - NLM
STAT- MEDLINE
DCOM- 20151110
LR  - 20181113
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Print)
IS  - 1056-8727 (Linking)
VI  - 29
IP  - 2
DP  - 2015 Mar
TI  - Complications and comorbidities of T2DM in adolescents: findings from the TODAY 
      clinical trial.
PG  - 307-12
LID - S1056-8727(14)00323-7 [pii]
LID - 10.1016/j.jdiacomp.2014.10.009 [doi]
AB  - With the rise in childhood obesity, type 2 diabetes mellitus (T2DM) has been 
      recognized to occur in adolescents with increasing frequency. Although much is 
      known about T2DM in adults, few studies have examined the treatment and 
      complications of T2DM in youth. The Treatment Options for type 2 Diabetes in 
      Adolescents and Youth (TODAY) study was designed to evaluate the efficacy of 
      various treatments and provided a unique opportunity to study the disease 
      progression and appearance of complications in a pediatric cohort with recent 
      onset of the disease. In the TODAY study, hypertension was present in 11.6% of 
      the population at baseline and increased to 33.8% by the end of the study. 
      Prevalence of high-risk LDL-cholesterol rose from 4.5% at baseline to 10.7% at 
      the end of the study. Microalbuminuria was found in 6.3% of the cohort at 
      baseline and increased to 16.6%. Retinopathy was not assessed upon entry into 
      TODAY, but was present in 13.9% of the TODAY cohort at the end of the study. 
      Experience to date indicates that these complications and comorbidities are 
      similar to those seen in adults, but occur on an accelerated timeline. The early 
      manifestation of diabetes complications in youth-onset T2DM suggests that this 
      group will be burdened with the tangible consequences of cardiovascular disease, 
      nephropathy, and retinopathy in the third and fourth decades of life. It is hoped 
      that through an early, aggressive approach to treatment and prevention, we may be 
      able to curb the onset and progression of these potentially devastating outcomes.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Tryggestad, Jeanie B
AU  - Tryggestad JB
AD  - University of Oklahoma Health Sciences Center, 1200 Children's Ave. Suite 4500, 
      Oklahoma City, OK 73104. Electronic address: Jeanie-tryggestad@ouhsc.edu.
FAU - Willi, Steven M
AU  - Willi SM
AD  - Children's Hospital of Philadelphia and Perelman School of Medicine at the 
      University of Pennsylvania, 34th Street & Civic Center Blvd. Suite 11NW30, 
      Philadelphia, PA 19104.
LA  - eng
GR  - U01 DK061254/DK/NIDDK NIH HHS/United States
GR  - U01-DK61239/DK/NIDDK NIH HHS/United States
GR  - U01-DK61242/DK/NIDDK NIH HHS/United States
GR  - U01-DK61254/DK/NIDDK NIH HHS/United States
GR  - U01-DK61212/DK/NIDDK NIH HHS/United States
GR  - U01 DK061242/DK/NIDDK NIH HHS/United States
GR  - U01-DK61230/DK/NIDDK NIH HHS/United States
GR  - U01 DK061212/DK/NIDDK NIH HHS/United States
GR  - U01 DK061230/DK/NIDDK NIH HHS/United States
GR  - UL1 RR025758/RR/NCRR NIH HHS/United States
GR  - U01 DK061239/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20141029
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
SB  - IM
MH  - Adolescent
MH  - *Adolescent Medicine/trends
MH  - Combined Modality Therapy
MH  - Comorbidity
MH  - Diabetes Complications/epidemiology/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/complications/epidemiology/physiopathology/*therapy
MH  - Disease Progression
MH  - Humans
MH  - *Precision Medicine
MH  - Randomized Controlled Trials as Topic
PMC - PMC4333013
MID - NIHMS642097
OTO - NOTNLM
OT  - Cardiovascular risk factors
OT  - Complications
OT  - Nephropathy
OT  - Retinopathy
OT  - Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study
OT  - Type 2 diabetes
COIS- Conflict of interest: JBT has no disclosures. SMW receives grant funding from 
      Novo-Nordisk, Bristol-Myers Squibb, and Takeda Global R&D.
EDAT- 2014/12/04 06:00
MHDA- 2015/11/11 06:00
PMCR- 2016/03/01
CRDT- 2014/12/04 06:00
PHST- 2014/07/29 00:00 [received]
PHST- 2014/10/10 00:00 [revised]
PHST- 2014/10/21 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/11/11 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - S1056-8727(14)00323-7 [pii]
AID - 10.1016/j.jdiacomp.2014.10.009 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2015 Mar;29(2):307-12. doi: 
      10.1016/j.jdiacomp.2014.10.009. Epub 2014 Oct 29.